HYHongtao Yu

Hongtao Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hongtao Yu has a total of 73 co-authors. Here are the top co-authors by number of shared publications:

  • Karen Melissa Hallow

    School of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, GA, United States

    4 shared publications
  • Bengt Hamrén

    Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca Gothenburg Sweden

    3 shared publications
  • George P. Huang

    Department of Mechanical and Materials Engineering, Wright State University, Dayton, OH, 45435

    3 shared publications
  • Zifeng Yang

    Department of Mechanical and Materials Engineering, Wright State University, Dayton, OH, 45435

    3 shared publications
  • Zifeng Yang

    Department of Mechanical and Materials Engineering, Wright State University, Dayton, OH, 45435, USA.

    3 shared publications
  • Anis A. Khan

    Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca Gaithersburg Maryland USA

    2 shared publications

Latest Publications

  • Open Access

    Phase 1, open‐label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions

    by Jianfeng Xu, Amina Haggag, Laurie Butcher, Haihui Liu, Wen Chen, Xuefeng Sun, Aruni Jha, Hongtao Yu, Anis Khan, Victoria E. R. Parker, et al.

    Aims: Elecoglipron (AZD5004/ECC5004) is an oral small‐molecule glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in development for weight management in people living with obesity or overweight and type 2 diabetes. This study aimed to characterize the pharmacokinetics (PK) profiles of two formulations of elecoglipron under fed and fasted conditions. Methods: We assessed the PK profiles, safety and tolerability of two formulations of elecoglipron, 50 mg, under fed and fasted conditions in healthy participants in a phase 1, open‐label, randomized, single‐dose, fixed‐sequence, crossover study. Results: Of 23 participants screened, 14 were randomized to elecoglipron and 13 (92.9%) completed the study. The half‐life for both formulations under fasted and fed conditions ranged between 20.7 and 21.2 h. Between the fed (reference) and fasted groups, geometric mean ratios (GMR) and 90% confidence intervals (CI) for the F1 formulation: area under the plasma–concentration curve (AUC) from time zero to the last measurement (AUC 0–last ) was 0.96 (0.82, 1.12), AUC from time zero extrapolated to infinity (AUC 0–inf ) was 0.95 (0.82, 1.11), and maximum plasma concentration (C max ) was 1.15 (0.90, 1.46). Similar results were observed for F2 in the fed and fasted groups. Safety and tolerability were comparable for the two formulations. The most common AEs were gastrointestinal (nausea, vomiting, dyspepsia, abdominal discomfort) and mostly mild in severity. Conclusions: Elecoglipron demonstrated a PK profile supportive of once‐daily dosing and may be administered under fed or fasted conditions. These findings support the continuing clinical development of elecoglipron. The trial is registered at ClinicalTrials.gov (NCT06268145). The trial was first registered on 20 February 2024.


  • Open Access

    Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients

    by Rick B. Vega, Gavin O’MAhony, April M. Barbour, Hongtao Yu, Jane Knöchel, Johan Brengdahl, Thomas Hochdörfer, Linnéa Bergenholm, Eva Töppner Carlsson, Andrea Ahnmark, et al.

    BACKGROUND: Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is an effective therapy for reducing low-density lipoprotein (LDL) cholesterol (LDL-C) in adults with hyperlipidemia, including heterozygous familial hypercholesterolemia, thereby lowering cardiovascular risk. Current PCSK9 inhibitors are injectable therapies; no oral small-molecule PCSK9 inhibitor has yet been approved. METHODS: Laroprovstat (AZD0780) is a novel small-molecule identified through structure-based design that binds to the PCSK9 C-terminal domain. The effects of laroprovstat on LDL receptor expression and LDL-C levels were assessed in vitro and in mice expressing human PCSK9 . Safety, tolerability, and pharmacokinetic and pharmacodynamic properties of laroprovstat were assessed in healthy participants with LDL-C ≥70 and ≤190 mg/dL after single ascending doses. Laroprovstat was also assessed in participants with LDL-C ≥100 and ≤190 mg/dL at doses of 1 mg or 30 mg versus placebo administered once daily for 28 days after a rosuvastatin 20 mg run-in treatment period. RESULTS: Laroprovstat does not inhibit the PCSK9–LDL receptor interaction but stabilizes the PCSK9 C-terminal domain, preventing lysosomal trafficking and degradation of LDL receptor. Laroprovstat increased LDL receptor expression and reduced LDL-C levels in mice expressing human PCSK9 . Laroprovstat displayed dose-proportional pharmacokinetics and a half-life suitable for once-daily dosing (≈40 hours). There was no clinically meaningful change in exposure when dosed with a high-fat meal compared with the fasted state (area under the plasma concentration-time curve inf and C max geometric mean reduction of 1.15 [90% CI, 1.11–1.19] and 1.06 [90% CI, 1.00–1.13], respectively). After a rosuvastatin 20 mg 3-week run-in treatment period, laroprovstat 1 and 30 mg reduced LDL-C by 29% (95% CI, 18%–38%) and 51% (95% CI, 44%–58%) compared with baseline. Combined rosuvastatin and laroprovstat treatment resulted in a total approximate reduction in LDL-C of 70% and 80% for laroprovstat 1 and 30 mg, respectively. CONCLUSIONS: Laroprovstat was well tolerated with no safety findings of concern and may be dosed with or without food. In treatment-naïve participants with hypercholesterolemia, combined rosuvastatin 20 mg and laroprovstat 30 mg treatment led to an 80% LDL-C reduction, supporting further development of laroprovstat as the first oral small-molecule PCSK9 inhibitor in patients with hypercholesterolemia. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05384262.


  • Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus

    by Hongtao Yu, Victoria Parker, Viknesh Selvarajah, Lars Hansen, Darren Robertson, Bengt Hamrén, Anis Khan, Joanna Parkinson

    Aims: Cotadutide is a dual glucagon‐like peptide‐1/glucagon receptor agonist. The objective of the analysis was to develop a pharmacokinetic‐pharmacodynamic (PK/PD) model to describe the relationship between cotadutide exposure and response on urine albumin‐to‐creatinine ratio (UACR), urinary albumin (UALB), and body weight in participants with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) using data from a Phase2b study (NCT04515849). Methods: A total of 247 participants with CKD and T2DM were randomized and titrated to either 100, 300 or 600 μg cotadutide, 1 mg semaglutide or placebo. UACR was measured biweekly from either morning void (Weeks 14 and 26) or spot urine (other visits). The analysis was implemented using a longitudinal non‐linear mixed‐effect model. The potential impact of covariates on efficacy in participants was quantified. Results: PK/PD models were developed, and a significant relationship was identified between cotadutide exposure and PD biomarkers of UACR, UALB and body weight. The models described the data adequately; greater changes in PD responses were observed with higher cotadutide doses. Baseline mean blood pressure and baseline UALB were found to affect the reductions in UACR and UALB, respectively. Model‐predicted relative change from placebo in UACR, UALB and body weight after 26 weeks of 600 μg cotadutide treatment were −45.6% (−52.4%, −38.7%), −47.2% (−56.0%, −39.9%) and −5.3% (−7.6%, −4.1%), respectively. Conclusions: This modelling assessment was successfully applied for cotadutide to understand the relationship between cotadutide dosing regimen and the response in UACR, UALB and body weight. These models have general application in analysing and interpreting data from CKD/diabetic kidney disease (DKD) studies.


  • Open Access

    Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach

    by Hongtao Yu, Sebastian Ueckert, Lina Zhou, Jenny Cheng, Darren Robertson, Lars Hansen, Armando Flor, Victoria Parker, Bengt Hamrén, Anis A. Khan

    Cotadutide is a dual glucagon‐like peptide‐1 (GLP‐1)/glucagon receptor agonist. Gastrointestinal adverse effects are known to be associated with GLP‐1 receptor agonism and can be mitigated through tolerance development via a gradual up‐titration. This analysis aimed to characterize the relationship between exposure and nausea incidence and to optimize titration schemes. The model was developed with pooled data from cotadutide‐administrated studies. Three different modeling approaches, proportional odds (PO), discrete‐time Markov, and two‐stage discrete‐time Markov models, were employed to characterize the exposure–nausea relationship. The severity of nausea was modeled as different states (non‐nausea, mild, and moderate/severe). The most appropriate model was selected to perform the covariate analysis, and the final covariate model was used to simulate the nausea event rates for various titration scenarios. The two Markov models demonstrated comparable performance and were better than the PO model. The covariate analysis was conducted with the standard Markov model for operational simplification and identified disease indications (NASH, obesity) and sex as covariates on Markov parameters. The simulations indicated that the biweekly titration with twofold dose escalation is superior to other titration schemes with a relatively low predicted nausea event rate at 600 μg (25%) and a shorter titration interval (8 weeks) to reach the therapeutic dose. The model can be utilized to optimize starting dose and titration schemes for other therapeutics in clinical trials to achieve an optimal risk–benefit balance and reach the therapeutic dose with minimal titration steps.


  • Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis

    by Hongtao Yu, Magnus Åstrand, Jenny Cheng, Kaila Nitin, Bengt Hamrén, Anis A. Khan

    Background Cotadutide is a dual glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptor agonist peptide. The objective of this analysis was to develop a population pharmacokinetic (popPK) model of cotadutide, and to identify any potential effect on the PK from intrinsic and extrinsic covariates. Methods The popPK analysis utilized a non-linear mixed-effects modeling approach using the data from 10 clinical studies in different participant categories following once-daily subcutaneous dose administration ranging from 20 to 600 μg. Additionally, the covariates affecting cotadutide exposure were quantified, and the model performance was evaluated through the prediction-corrected visual predictive checks. Results A one-compartment model with first-order absorption and elimination adequately described the data as confirmed via visual predictive check plots and parameter plausibility. The mean values for cotadutide apparent clearance (CL/F), apparent volume of distribution (V/F), absorption rate constant (Ka), and half-life were 1.05 L/h, 20.0 L, 0.38 h–1, and 13.3 hours, respectively. Covariate modeling identified body weight, alanine transaminase, albumin, anti-drug antibody (ADA) titer values, formulation strength and injection device, and participant categories as significant covariates on PK parameters, where ADAs have been identified to decrease cotadutide clearance. The model demonstrated that a 150-kg participant was estimated to have 30% lower for both AUC and Cmax and a 66 kg participant was estimated to have 35% higher for both AUC and Cmax relative to a reference individual with a median weight of 96 kg. Conclusions A popPK model was developed for cotadutide with cotadutide clinical data, and the impact of the statistically significant covariates identified was not considered clinically meaningful. The popPK model will be used to evaluate exposure–response relationships for cotadutide clinical data.


  • Open Access

    Understanding heterogeneous mechanisms of heart failure with preserved ejection fraction through cardiorenal mathematical modeling

    by Sanchita Basu, Hongtao Yu, Jonathan R. Murrow, K. Melissa Hallow

    In contrast to heart failure (HF) with reduced ejection fraction (HFrEF), effective interventions for HF with preserved ejection fraction (HFpEF) have proven elusive, in part because it is a heterogeneous syndrome with incompletely understood pathophysiology. This study utilized mathematical modeling to evaluate mechanisms distinguishing HFpEF and HFrEF. HF was defined as a state of chronically elevated left ventricle end diastolic pressure (LVEDP > 20mmHg). First, using a previously developed cardiorenal model, sensitivities of LVEDP to potential contributing mechanisms of HFpEF, including increased myocardial, arterial, or venous stiffness, slowed ventricular relaxation, reduced LV contractility, hypertension, or reduced venous capacitance, were evaluated. Elevated LV stiffness was identified as the most sensitive factor. Large LV stiffness increases alone, or milder increases combined with either decreased LV contractility, increased arterial stiffness, or hypertension, could increase LVEDP into the HF range without reducing EF. We then evaluated effects of these mechanisms on mechanical signals of cardiac outward remodeling, and tested the ability to maintain stable EF (as opposed to progressive EF decline) under two remodeling assumptions: LV passive stress-driven vs. strain-driven remodeling. While elevated LV stiffness increased LVEDP and LV wall stress, it mitigated wall strain rise for a given LVEDP. This suggests that if LV strain drives outward remodeling, a stiffer myocardium will experience less strain and less outward dilatation when additional factors such as impaired contractility, hypertension, or arterial stiffening exacerbate LVEDP, allowing EF to remain normal even at high filling pressures. Thus, HFpEF heterogeneity may result from a range of different pathologic mechanisms occurring in an already stiffened myocardium. Together, these simulations further support LV stiffening as a critical mechanism contributing to elevated cardiac filling pressures; support LV passive strain as the outward dilatation signal; offer an explanation for HFpEF heterogeneity; and provide a mechanistic explanation distinguishing between HFpEF and HFrEF.


  • Open Access

    Effect of the Extended Rigid Flapping Trailing Edge Fringe on an S833 Airfoil

    by Hongtao Yu, Zifeng Yang

    A 2D numerical simulation was conducted to investigate the effect of an extended rigid trailing edge fringe with a flapping motion on the S833 airfoil and its wake flow field, as an analogy of an owl’s wing. This study aims to characterize the influence of the extended flapping fringe on the aerodynamic performance and the wake flow characteristics downstream of the airfoil. The length (Le) and flapping frequencies (fe) of the fringe are the key parameters that dominate the impact on the airfoil and the flow field, given that the oscillation angular amplitude is fixed at 5°. The simulation results demonstrated that the airfoil with an extended fringe of 10% of the chord at a flapping frequency of fe = 110 Hz showed a substantial effect on the pressure distribution on the airfoil and the flow characteristics downstream of the airfoil. An irregular vortex street was predicted downstream, thus causing attenuations of the vorticities, and shorter streamwise gaps between each pair of vortices. The extended flapping fringe at a lower frequency than the natural shedding vortex frequency can effectively break the large vortex structure up into smaller scales, thus leading to an accelerated attenuation of vorticities in the wake.


  • Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis

    by Hongtao Yu, Sanchita Basu, Weifeng Tang, Robert C. Penland, Peter J. Greasley, Jan Oscarsson, David W. Boulton, K. Melissa Hallow

    Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) have been shown to reduce the risk of worsening heart failure (HF) in subjects with HF and a reduced ejection fraction (HFrEF) in multiple clinical trials. The DAPACARD clinical trial was conducted to examine the effects of dapagliflozin on cardiac substrate uptake, myocardial efficiency, and myocardial contractile work in subjects with type 2 diabetes mellitus. As a complement to the clinical study, a mechanistic mathematical model of cardiorenal physiology was used to quantify the influence of established natriuretic/diuretic effects of SGLT2i on cardiac function (myocardial efficiency and global longitudinal strain). Virtual participants reflecting the participant‐level characteristics in the DAPACARD trial were produced by varying model parameters over physiologically plausible ranges. A second virtual population was generated by inducing a state of HFrEF in the DAPACARD virtual participants with type 2 diabetes mellitus for comparison. Cardiac responses to placebo and SGLT2i were simulated over 42 days. Cardiac hemodynamic improvements were predicted in DAPACARD‐HFrEF virtual participants but not in DAPACARD virtual participants. In particular, the natriuresis/diuresis induced by SGLT2i improved the global longitudinal strain and myocardial efficiency in DAPACARD‐HFrEF virtual participants within the first 14 days (change from baseline: global longitudinal strain, –0.95%; and myocardial efficiency, 0.34%), whereas the global longitudinal strain and myocardial efficiency in DAPACARD virtual participants were slightly worse (change from baseline: global longitudinal strain, 0.35%; and myocardial efficiency: –0.01%). The results of the DAPACARD virtual participants modeling were in line with the clinical data but do not preclude additional effects from other mechanisms of SGLT2i.


  • Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA‐HF Study Population: A Mathematical Modeling Analysis

    by Hongtao Yu, Weifeng Tang, Peter J. Greasley, Robert C. Penland, David W. Boulton, K. Melissa Hallow

    The Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA‐HF) study demonstrated that dapagliflozin, a sodium‐glucose cotransporter‐2 inhibitor (SGLT2i), reduced heart failure hospitalization and cardiovascular death in patients with heart failure with reduced ejection fraction (HF‐rEF), with and without type 2 diabetes mellitus. Multiple potential mechanisms have been proposed to explain this benefit, which may be multifactorial. This study aimed to quantify the contribution of the known natriuretic/diuretic effects of SGLT2is to changes in cardiac hemodynamics, remodeling, and fluid homeostasis in the setting of HF‐rEF. An integrated cardiorenal mathematical model was used to simulate inhibition of SGLT2 and its consequences on cardiac hemodynamics in a virtual population of HF‐rEF patients generated by varying model parameters over physiologically plausible ranges and matching to baseline characteristics of individual DAPA‐HF trial patients. Cardiovascular responses to placebo and SGLT2i over time were then simulated. The baseline characteristics of the HF‐rEF virtual population and DAPA‐HF were in good agreement. SGLT2i‐induced diuresis and natriuresis that reduced blood volume and interstitial fluid volume, relative to placebo within 14 days. This resulted in decreased left ventricular end‐diastolic volume and pressure, indicating reduced cardiac preload. Thereafter, blood volume and interstitial fluid volume again began to accumulate, but pressures and volumes remained shifted lower relative to placebo. After 1 year, left ventricle mass was lower and ejection fraction was higher than placebo. These simulations considered only hemodynamic consequences of the natriuretic/diuretic effects of SGLT2i, as other mechanisms may contribute additional benefits besides those predictions.


  • Open Access

    Cardiac and renal function interactions in heart failure with reduced ejection fraction: A mathematical modeling analysis

    by Hongtao Yu, Sanchita Basu, K. Melissa Hallow

    Congestive heart failure is characterized by suppressed cardiac output and arterial filling pressure, leading to renal retention of salt and water, contributing to further volume overload. Mathematical modeling provides a means to investigate the integrated function and dysfunction of heart and kidney in heart failure. This study updates our previously reported integrated model of cardiac and renal functions to account for the fluid exchange between the blood and interstitium across the capillary membrane, allowing the simulation of edema. A state of heart failure with reduced ejection fraction (HF-rEF) was then produced by altering cardiac parameters reflecting cardiac injury and cardiovascular disease, including heart contractility, myocyte hypertrophy, arterial stiffness, and systemic resistance. After matching baseline characteristics of the SOLVD clinical study, parameters governing rates of cardiac remodeling were calibrated to describe the progression of cardiac hemodynamic variables observed over one year in the placebo arm of the SOLVD clinical study. The model was then validated by reproducing improvements in cardiac function in the enalapril arm of SOLVD. The model was then applied to prospectively predict the response to the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin, which has been shown to reduce heart failure events in HF-rEF patients in the recent DAPAHF clinical trial by incompletely understood mechanisms. The simulations predict that dapagliflozin slows cardiac remodeling by reducing preload on the heart, and relieves congestion by clearing interstitial fluid without excessively reducing blood volume. This provides a quantitative mechanistic explanation for the observed benefits of SGLT2i in HF-rEF. The model also provides a tool for further investigation of heart failure drug therapies. Recently, the DAPAHF and EMPA-REG clinical trials showed that the Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) class of drugs are beneficial in reducing the heart failure with reduced ejection fraction (HFrEF) hospitalization and lowering the risk of worsening HF or death. Despite the beneficial outcomes observed clinically, the hemodynamic mechanisms of SGLT2i underlying the DAHAHF results remain unclear. Mathematical modeling has long been used to investigate the integrated organ function and dysfunction and understand the effects of interventions. A proposed cardio-renal mathematical model was adopted and improved to capture the state of HFrEF and cardiac therapeutic responses. Validation studies were carried out by reproducing improvements in cardiac functions in the enalapril arm of the SOLVD clinical trial. The influences of SGLT2i on cardiac and renal functional interactions were investigated. It was observed that SGLT2i reduces left ventricle (LV) end-diastolic volume/pressure (EDV/EDP), and that this preload reduction slows cardiac remodeling and progression over one year. It further presents that SGLT2i may reduce interstitial congestion without inducing large reductions in blood volume.